A genetic disruption strategy developed by CU Boulder researchers effectively stymies the evolution of antibiotic-resistant bacteria such as E. coli, giving scientists a crucial leg up in the ongoing battle against deadly superbugs.
These multidrug-resistant pathogens—which adapt to current antibiotics faster than new ones can be created—infect nearly 2 million people and cause at least 23,000 deaths annually in the U.S., according to data from the Centers for Disease Control.
In an effort to develop a sustainable long-term solution, CU Boulder researchers created the Controlled Hindrance of Adaptation of OrganismS (CHAOS) approach, which uses CRISPR DNA editing techniques to modify multiple gene expressions within the bacteria cells, stunting the pathogen’s central processes and thwarting its ability to evolve defenses.
“We now have a way to cut off the evolutionary pathways of some of the nastiest bugs and potentially prevent future bugs from emerging at all,” said Peter Otoupal, lead author of the study and a doctoral researcher in CU Boulder’s Department of Chemical and Biological Engineering (CHBE).
The CHAOS research is the culmination of work that began in 2013, when Otoupal and his colleagues began searching for genes that could act as a cellular kill switch for E. coli. When the scientists tweaked one gene at a time, the bacteria could adapt and survive. But when they altered two or more genes at once, the cell got weaker.
“We saw that when we tweaked multiple gene expressions at the same time—even genes that would seemingly help the bacteria survive—the bacteria’s fitness dropped dramatically,” Otoupal said.
The CHAOS method takes advantage of this effect, pulling multiple genetic levers in order to build up stress on the bacterial cell and eventually trigger a cascading failure, leaving the bug more vulnerable to current treatments. The technique does not alter the bug’s DNA itself, only the expression of individual genes, similar to the way a coded message is rendered useless without the proper decryption.
“You can think of it in terms of a series of escalating annoyances to the cell that eventually cause it to weaken,” said Anushree Chatterjee, senior author of the study and an assistant professor in CHBE. “This method offers tremendous potential to create more effective combinatorial approaches.”
Although E. coli has nearly 4,000 individual genes, the exact gene modification sequence appears to matter less than the sheer number of genes that are disrupted, Otoupal said. Still, the researchers plan to continue optimizing the CHAOS method to seek out the most efficient disruptions.“Diseases are very dynamic, so we need to design smarter therapies that can gain control over their rapid adaptation rates,” Chatterjee said. “The emphasis in our lab is demonstrating the efficacy of these methods and then finding ways to translate the technology to modern clinical settings.”
“In the past, nobody really considered that it might be possible to slow down evolution,” Otoupal said. “But like anything else, evolution has rules and we’re starting to learn how to use them to our advantage.”
Learn more: How to stop an antibiotic-resistant superbug
The Latest on: Genetic disruption
via Google News
The Latest on: Genetic disruption
- New class of highly effective inhibitors protects against neurodegenerationon October 8, 2020 at 11:16 am
Neurobiologists at Heidelberg University have discovered how a special receptor at neuronal junctions that normally activates a protective genetic ... after a stroke, disruptions in circulation ...
- Chromosome defects seen from over-exchange of DNA in sperm and eggson October 8, 2020 at 9:44 am
The exchange of DNA between chromosomes during the early formation of sperm and egg cells normally is limited to assure fertility.
- Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.on October 8, 2020 at 5:18 am
New Name Reflects Company’s Expanding Global Presence and Therapeutic Portfolio - Seagen Inc. is the new corporate name for Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company ...
- New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencingon October 8, 2020 at 4:30 am
PRNewswire/ -- Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germline genetic tests identify, ...
- Nobel Prize in Chemistry awarded to two women scientists for their work on genome editingon October 7, 2020 at 9:15 pm
“There is enormous power in this genetic tool, which affects us all,” said Claes ... “A major advance can introduce major disruptions, and we need to decide how to embrace it in such a way that ...
- Vitamin D deficiency may predict COVID-19 seroconversionon October 7, 2020 at 9:15 pm
A recent study published on the preprint server medRxiv* in October 2020 reports the potential contribution of vitamin D deficiency to an increased risk of COVID-19 in a subset of health care workers ...
- Nobel Prize in Chemistry Awarded to 2 Scientists for Work on Genome Editingon October 7, 2020 at 3:01 am
Emmanuelle Charpentier and Jennifer A. Doudna developed the Crispr tool, which can change the DNA of animals, plants and microorganisms with high precision.
- Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwideon October 5, 2020 at 4:59 am
PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, ...
- The Bradykinin Hypothesis: What It Is And What It Can Tell Uson October 2, 2020 at 9:35 am
Scientists have been working to figure out how the virus affects a variety of body systems, and think that bradykinin might have something to do with it.
via Bing News